{"version":"1.0","provider_name":"ZoBio - Drug Discovery Technology","provider_url":"https:\/\/zobio.com\/online","author_name":"Content manager ~KB","author_url":"https:\/\/zobio.com\/online\/author\/kasia\/","title":"Mettl3\/Mettl14 \u2013 An epitranscriptomic writer complex - ZoBio - Drug Discovery Technology","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"CX272gqOLA\"><a href=\"https:\/\/zobio.com\/online\/cases\/mettl3-mettl14-an-epitranscriptomic-writer-complex\/\">Mettl3\/Mettl14 \u2013 An epitranscriptomic writer complex<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/zobio.com\/online\/cases\/mettl3-mettl14-an-epitranscriptomic-writer-complex\/embed\/#?secret=CX272gqOLA\" width=\"600\" height=\"338\" title=\"&#8220;Mettl3\/Mettl14 \u2013 An epitranscriptomic writer complex&#8221; &#8212; ZoBio - Drug Discovery Technology\" data-secret=\"CX272gqOLA\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/zobio.com\/online\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/2651.jpg","thumbnail_width":1200,"thumbnail_height":628,"description":"Challenge Mettl3\/Mettl14 is a large (90 kDa) heterodimeric \u201cwriter\u201d complex that uses S-adenosyl methionine (SAM) as a cofactor. Identifying low affinity, validated fragment hits in the large amount of electron density derived from X-ray diffraction data was extremely difficult.  Achievements We developed a highly efficient structure pipeline capable of determining up to 10 sub 2\u00c5 structures per month which has been the basis for elaborating fragment hits to cellular activity and beyond. Multiple chemotypes are promising, allowing for a robust hit-to-lead campaign."}